Switch theme
Sign up to access all valuation multiples
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
2019
163
LTM Revenue $15.9M
LTM EBITDA -$185M
$424M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Structure Therapeutics has a last 12-month revenue (LTM) of $15.9M and a last 12-month EBITDA of -$185M.
In the most recent fiscal year, Structure Therapeutics achieved revenue of n/a and an EBITDA of -$157M.
Structure Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Structure Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $15.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $15.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$185M | XXX | -$157M | XXX | XXX | XXX |
| EBITDA Margin | -1161% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$171M | XXX | -$158M | XXX | XXX | XXX |
| EBIT Margin | -1074% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$140M | XXX | -$123M | XXX | XXX | XXX |
| Net Margin | -880% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Structure Therapeutics's stock price is $22.
Structure Therapeutics has current market cap of $1.3B, and EV of $424M.
See Structure Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $424M | $1.3B | XXX | XXX | XXX | XXX | $-0.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Structure Therapeutics has market cap of $1.3B and EV of $424M.
Structure Therapeutics's trades at n/a EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Structure Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Structure Therapeutics has a P/E ratio of -9.0x.
See valuation multiples for Structure Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $424M | XXX | $424M | XXX | XXX | XXX |
| EV/Revenue | 26.6x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | 26.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.0x | XXX | -10.2x | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | -3.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStructure Therapeutics's last 12 month revenue growth is 42%
Structure Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
Structure Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Structure Therapeutics's rule of X is -1057% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Structure Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1161% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1057% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Structure Therapeutics acquired XXX companies to date.
Last acquisition by Structure Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Structure Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Structure Therapeutics founded? | Structure Therapeutics was founded in 2019. |
| Where is Structure Therapeutics headquartered? | Structure Therapeutics is headquartered in United States of America. |
| How many employees does Structure Therapeutics have? | As of today, Structure Therapeutics has 163 employees. |
| Who is the CEO of Structure Therapeutics? | Structure Therapeutics's CEO is Professor Raymond C. Stevens, PhD. |
| Is Structure Therapeutics publicy listed? | Yes, Structure Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Structure Therapeutics? | Structure Therapeutics trades under GPCR ticker. |
| When did Structure Therapeutics go public? | Structure Therapeutics went public in 2023. |
| Who are competitors of Structure Therapeutics? | Similar companies to Structure Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Structure Therapeutics? | Structure Therapeutics's current market cap is $1.3B |
| What is the current revenue of Structure Therapeutics? | Structure Therapeutics's last 12 months revenue is $15.9M. |
| What is the current revenue growth of Structure Therapeutics? | Structure Therapeutics revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Structure Therapeutics? | Current revenue multiple of Structure Therapeutics is 26.6x. |
| Is Structure Therapeutics profitable? | Yes, Structure Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Structure Therapeutics? | Structure Therapeutics's last 12 months EBITDA is -$185M. |
| What is Structure Therapeutics's EBITDA margin? | Structure Therapeutics's last 12 months EBITDA margin is -1161%. |
| What is the current EV/EBITDA multiple of Structure Therapeutics? | Current EBITDA multiple of Structure Therapeutics is -2.3x. |
| What is the current FCF of Structure Therapeutics? | Structure Therapeutics's last 12 months FCF is -$551M. |
| What is Structure Therapeutics's FCF margin? | Structure Therapeutics's last 12 months FCF margin is -3462%. |
| What is the current EV/FCF multiple of Structure Therapeutics? | Current FCF multiple of Structure Therapeutics is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
